olmesartan medoxomil has been researched along with Pancreatic Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamada, S; Kikuta, K; Masamune, A; Miura, S; Nakano, E; Shimosegawa, T; Takikawa, T | 1 |
1 other study(ies) available for olmesartan medoxomil and Pancreatic Neoplasms
| Article | Year |
|---|---|
The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice.
Topics: Actins; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Line, Tumor; Cell Proliferation; Collagen Type I; Humans; Imidazoles; Male; Mice; Mice, Nude; Olmesartan Medoxomil; Pancreatic Neoplasms; Pancreatic Stellate Cells; Tetrazoles | 2013 |